Targeted protein degraders do not simply occupy a disease protein and block its activity. They recruit the cell’s disposal machinery to remove it, potentially opening targets conventional drugs cannot reach.
For much of the past two decades, monoclonal antibodies have dominated modern drug development. Their ability to bind with high specificity, block protein function, and engage immune mechanisms has transformed the treatment of cancer, autoimmune disorders, and infectious disease. But despite their blockbuster status, biologics have a blind spot. They are largely excluded from the